The Relationship Between Different Subtypes of and PD-L1 & Tumor Mutation Burden (TMB) Based on Next-generation Sequencing (NGS) Detection in Chinese Lung Cancer Patients

Overview

Journal Transl Lung Cancer Res

Date 2022 Mar 14

PMID 35280306

Authors

Ying Yang

Shengping Shen

Yingjia Sun

Hatim Husain

Haiyan Zhou

Shun Lu

Ziming Li

Affiliations

Soon will be listed here.

Abstract

Background: gene mutations are the most common driver oncogenes in non-small cell lung cancer (NSCLC). We conducted an analysis of the immunological characteristics including tumor mutation burden and programmed death-ligand 1 (PD-L1) expression of different subtypes of in 2880 -mutant NSCLC patients.

Methods: A total of 2,880 patients with NSCLC were included in the study. Somatic mutation data were provided by Berry Oncology (Fujian, China), Geneplus BioTech (Beijing, China), Nanjing Geneseeq Technology Inc (Nanjing, China), and Burning Rock Biotech (Guangzhou, China). Z-scores were used to unify all data. SPSS 20.0 (SPSS, Chicago, IL, USA) software was used for statistical analyses. All scatter plots and boxplot maps were drawn using GraphPad Prism 8. Tumor mutation burden (TMB) expression was defined by the number of somatic mutations. The PD-L1 clone 22C3 pharmDx kit was used to measure the expression level of PD-L1. Mann-Whitney U test was used for statistical analysis. P value <0.05 was considered statistically significant.

Results: We identified 2,880 patients with -mutant NSCLC. The percentage level of TMB and expression of PD-L1 was significantly decreased in -mutant lung cancer tissue and blood samples (n=162). The percentage level of TMB and expression of PD-L1 in -mutant lung cancer specimens was significantly increased (n=190).

Conclusions: The findings demonstrate a decreased level of TMB and expression of PD-L1 in -mutant lung cancer and the increased level of TMB and expression of PD-L1 in -mutant lung cancer. Further work is needed to identify if the subtype of mutation could be a potential therapeutic biomarker in lung cancer patients with mutation. TMB data was consistently verified in tissue and blood samples and confirmed the feasibility of next-generation sequencing (NGS) verification in plasma samples. Our research may help to provide more individualized treatment options for NSCLC patients.

Citing Articles

PD-1/L1 immune checkpoint inhibitors for KRAS-mutant non-small cell lung cancer: a multicenter retrospective real-world study.

Wei K, Sun T, Feng X, Chen Y, Liu Q, Tang H BMC Cancer. 2025; 25(1):444.

PMID: 40075326 PMC: 11899077. DOI: 10.1186/s12885-025-13868-9.

Analysis of the benefit of anti-PD-1 monotherapy according to NGS-diagnosed genetic alterations in patients with non-small cell lung cancer.

De Saint Basile H, Elaidi R, Maaradji Z, Blons H, BenDhiab R, Gibault L Explor Target Antitumor Ther. 2025; 5(6):1435-1449.

PMID: 39764418 PMC: 11702263. DOI: 10.37349/etat.2024.00283.

Refining PD-1/PD-L1 assessment for biomarker-guided immunotherapy: A review.

Zdrenka M, Kowalewski A, Ahmadi N, Sadiqi R, Chmura L, Borowczak J Biomol Biomed. 2023; 24(1):14-29.

PMID: 37877810 PMC: 10787614. DOI: 10.17305/bb.2023.9265.

Establishing a predictive model for tumor mutation burden status based on CT radiomics and clinical features of non-small cell lung cancer patients.

Yang J, Shi W, Yang Z, Yu H, Wang M, Wei Y Transl Lung Cancer Res. 2023; 12(4):808-823.

PMID: 37197623 PMC: 10183386. DOI: 10.21037/tlcr-23-171.

Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions.

Watterson A, Coelho M Cell Commun Signal. 2023; 21(1):45.

PMID: 36864508 PMC: 9979509. DOI: 10.1186/s12964-023-01063-x.

References

El Osta B, Behera M, Kim S, Berry L, Sica G, Pillai R . Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2019; 14(5):876-889. PMC: 8108452. DOI: 10.1016/j.jtho.2019.01.020. View

Liu C, Zheng S, Jin R, Wang X, Wang F, Zang R . The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Cancer Lett. 2019; 470:95-105. DOI: 10.1016/j.canlet.2019.10.027. View

. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511(7511):543-50. PMC: 4231481. DOI: 10.1038/nature13385. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

Ricciuti B, Leonardi G, Metro G, Grignani F, Paglialunga L, Bellezza G . Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications. Expert Rev Respir Med. 2015; 10(1):53-68. DOI: 10.1586/17476348.2016.1115349. View

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J . Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2016; 389(10066):255-265. PMC: 6886121. DOI: 10.1016/S0140-6736(16)32517-X. View

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

Wood K, Hensing T, Malik R, Salgia R . Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review. JAMA Oncol. 2016; 2(6):805-12. DOI: 10.1001/jamaoncol.2016.0405. View

Ihle N, Byers L, Kim E, Saintigny P, Lee J, Blumenschein G . Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012; 104(3):228-39. PMC: 3274509. DOI: 10.1093/jnci/djr523. View

10.

Dogan S, Shen R, Ang D, Johnson M, DAngelo S, Paik P . Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res. 2012; 18(22):6169-77. PMC: 3500422. DOI: 10.1158/1078-0432.CCR-11-3265. View

11.

Uprety D, Adjei A . KRAS: From undruggable to a druggable Cancer Target. Cancer Treat Rev. 2020; 89:102070. DOI: 10.1016/j.ctrv.2020.102070. View

12.

Tape C, Ling S, Dimitriadi M, McMahon K, Worboys J, Leong H . Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation. Cell. 2016; 165(4):910-20. PMC: 4868820. DOI: 10.1016/j.cell.2016.03.029. View

13.

Grommes C, DeAngelis L . Primary CNS Lymphoma. J Clin Oncol. 2017; 35(21):2410-2418. PMC: 5516483. DOI: 10.1200/JCO.2017.72.7602. View

14.

La Fleur L, Falk-Sorqvist E, Smeds P, Berglund A, Sundstrom M, Mattsson J . Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11. Lung Cancer. 2019; 130:50-58. DOI: 10.1016/j.lungcan.2019.01.003. View

15.

Tseng J, Yang T, Wu C, Ku W, Chen K, Hsu K . Characteristics and Predictive Value of PD-L1 Status in Real-World Non-Small Cell Lung Cancer Patients. J Immunother. 2018; 41(6):292-299. DOI: 10.1097/CJI.0000000000000226. View

16.

Dong Z, Zhong W, Zhang X, Su J, Xie Z, Liu S . Potential Predictive Value of and Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res. 2017; 23(12):3012-3024. DOI: 10.1158/1078-0432.CCR-16-2554. View

17.

Drilon A, Wang L, Hasanovic A, Suehara Y, Lipson D, Stephens P . Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 2013; 3(6):630-5. PMC: 4160032. DOI: 10.1158/2159-8290.CD-13-0035. View

18.

Downward J . Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003; 3(1):11-22. DOI: 10.1038/nrc969. View

19.

Jeanson A, Tomasini P, Souquet-Bressand M, Brandone N, Boucekine M, Grangeon M . Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol. 2019; 14(6):1095-1101. DOI: 10.1016/j.jtho.2019.01.011. View

20.

Wu S, Liao R, Tu H, Wang W, Dong Z, Huang S . Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy. J Thorac Oncol. 2017; 13(4):521-532. DOI: 10.1016/j.jtho.2017.11.132. View